Clinical Trial Update: High-Risk Skin Cancers With Atezolizumab Plus NT-I7 [Phase 1, Phase 2]

View source ↗

Summary

A terminated Phase 1/2 trial evaluating the combination of atezolizumab and NT-I7 for high-risk skin cancers (melanoma, Merkel cell carcinoma, and cutaneous squ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma
• Melanoma
• Merkel Cell Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• NT-I7

Snippet

Sponsor: NeoImmuneTech | Conditions: Melanoma, Merkel Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-10-22